Differentiation therapy revisited
Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies. The concept of differentia...
Gespeichert in:
Veröffentlicht in: | Nature Reviews. Cancer 2018-02, Vol.18 (2), p.117-127 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 127 |
---|---|
container_issue | 2 |
container_start_page | 117 |
container_title | Nature Reviews. Cancer |
container_volume | 18 |
creator | de Thé, Hugues |
description | Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
The concept of differentiation therapy emerged from the fact that hormones or cytokines may promote differentiation
ex vivo
, thereby irreversibly changing the phenotype of cancer cells. Its hallmark success has been the treatment of acute promyelocytic leukaemia (APL), a condition that is now highly curable by the combination of retinoic acid (RA) and arsenic. Recently, drugs that trigger differentiation in a variety of primary tumour cells have been identified, suggesting that they are clinically useful. This Opinion article analyses the basis for the clinical successes of RA or arsenic in APL by assessing the respective roles of terminal maturation and loss of self-renewal. By reviewing other successful examples of drug-induced tumour cell differentiation, novel approaches to transform differentiating drugs into more efficient therapies are proposed. |
doi_str_mv | 10.1038/nrc.2017.103 |
format | Article |
fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_1971658418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A524724911</galeid><sourcerecordid>A524724911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-f944553102bb11070031f75a21ca9e559b5da84d28fdca3779d950ead910cd5a3</originalsourceid><addsrcrecordid>eNptkd9rHCEQx6WkND_atz6XhEJoIXt1XF3XxyNJm8JBXhLom3g65gx761V3A_nv63LppSnRB53xMyPz_RLyEegMaN1-65OdMQpyit6QA-CSVyCbdm93F7_2yWHO95RCAxLekX2mQDEG9QE5uQjeY8J-CGYIsT8eVpjM5vE44UPIYUD3nrz1psv44ek8IrffL2_Or6rF9Y-f5_NFZXmrhsorzoWogbLlEoBKSmvwUhgG1igUQi2FMy13rPXOmlpK5ZSgaJwCap0w9RH5uu27Mp3epLA26VFHE_TVfKGnHK0bUbeNeIDCftmymxR_j5gHvQ7ZYteZHuOYNSgJjWg5tAX9_B96H8fUl0k0o0WDsrh8pu5Mhzr0Pg7J2KmpngvGJeMKpm9nr1BlO1wHG3v0oeRfFJz-U7BC0w2rHLtxUjq_BM-2oE0x54R-pwBQPdmsi816snmKCv7paahxuUa3g__6WoBqC-Ty1N9hep761YZ_ABbEq9M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2022111147</pqid></control><display><type>article</type><title>Differentiation therapy revisited</title><source>Nature</source><source>Alma/SFX Local Collection</source><creator>de Thé, Hugues</creator><creatorcontrib>de Thé, Hugues</creatorcontrib><description>Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
The concept of differentiation therapy emerged from the fact that hormones or cytokines may promote differentiation
ex vivo
, thereby irreversibly changing the phenotype of cancer cells. Its hallmark success has been the treatment of acute promyelocytic leukaemia (APL), a condition that is now highly curable by the combination of retinoic acid (RA) and arsenic. Recently, drugs that trigger differentiation in a variety of primary tumour cells have been identified, suggesting that they are clinically useful. This Opinion article analyses the basis for the clinical successes of RA or arsenic in APL by assessing the respective roles of terminal maturation and loss of self-renewal. By reviewing other successful examples of drug-induced tumour cell differentiation, novel approaches to transform differentiating drugs into more efficient therapies are proposed.</description><identifier>ISSN: 1474-175X</identifier><identifier>EISSN: 1474-1768</identifier><identifier>DOI: 10.1038/nrc.2017.103</identifier><identifier>PMID: 29192213</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/136/142 ; 631/67/1059 ; 631/67/1990/283/1897 ; 631/67/395 ; Arsenic ; Binding sites ; Biomedicine ; Cancer ; Cancer Research ; Cancer therapies ; Cell differentiation ; Cell self-renewal ; Chemotherapy ; Cytokines ; Health aspects ; Kinases ; Leukemia ; Life Sciences ; Oncology, Experimental ; opinion-2 ; Phenotypes ; Proteins ; Retinoic acid ; Stem cells ; Success ; Tumors</subject><ispartof>Nature Reviews. Cancer, 2018-02, Vol.18 (2), p.117-127</ispartof><rights>Springer Nature Limited 2017</rights><rights>COPYRIGHT 2018 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Feb 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-f944553102bb11070031f75a21ca9e559b5da84d28fdca3779d950ead910cd5a3</citedby><cites>FETCH-LOGICAL-c489t-f944553102bb11070031f75a21ca9e559b5da84d28fdca3779d950ead910cd5a3</cites><orcidid>0000-0002-1113-4472</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29192213$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03653865$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>de Thé, Hugues</creatorcontrib><title>Differentiation therapy revisited</title><title>Nature Reviews. Cancer</title><addtitle>Nat Rev Cancer</addtitle><addtitle>Nat Rev Cancer</addtitle><description>Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
The concept of differentiation therapy emerged from the fact that hormones or cytokines may promote differentiation
ex vivo
, thereby irreversibly changing the phenotype of cancer cells. Its hallmark success has been the treatment of acute promyelocytic leukaemia (APL), a condition that is now highly curable by the combination of retinoic acid (RA) and arsenic. Recently, drugs that trigger differentiation in a variety of primary tumour cells have been identified, suggesting that they are clinically useful. This Opinion article analyses the basis for the clinical successes of RA or arsenic in APL by assessing the respective roles of terminal maturation and loss of self-renewal. By reviewing other successful examples of drug-induced tumour cell differentiation, novel approaches to transform differentiating drugs into more efficient therapies are proposed.</description><subject>631/136/142</subject><subject>631/67/1059</subject><subject>631/67/1990/283/1897</subject><subject>631/67/395</subject><subject>Arsenic</subject><subject>Binding sites</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cell differentiation</subject><subject>Cell self-renewal</subject><subject>Chemotherapy</subject><subject>Cytokines</subject><subject>Health aspects</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Life Sciences</subject><subject>Oncology, Experimental</subject><subject>opinion-2</subject><subject>Phenotypes</subject><subject>Proteins</subject><subject>Retinoic acid</subject><subject>Stem cells</subject><subject>Success</subject><subject>Tumors</subject><issn>1474-175X</issn><issn>1474-1768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkd9rHCEQx6WkND_atz6XhEJoIXt1XF3XxyNJm8JBXhLom3g65gx761V3A_nv63LppSnRB53xMyPz_RLyEegMaN1-65OdMQpyit6QA-CSVyCbdm93F7_2yWHO95RCAxLekX2mQDEG9QE5uQjeY8J-CGYIsT8eVpjM5vE44UPIYUD3nrz1psv44ek8IrffL2_Or6rF9Y-f5_NFZXmrhsorzoWogbLlEoBKSmvwUhgG1igUQi2FMy13rPXOmlpK5ZSgaJwCap0w9RH5uu27Mp3epLA26VFHE_TVfKGnHK0bUbeNeIDCftmymxR_j5gHvQ7ZYteZHuOYNSgJjWg5tAX9_B96H8fUl0k0o0WDsrh8pu5Mhzr0Pg7J2KmpngvGJeMKpm9nr1BlO1wHG3v0oeRfFJz-U7BC0w2rHLtxUjq_BM-2oE0x54R-pwBQPdmsi816snmKCv7paahxuUa3g__6WoBqC-Ty1N9hep761YZ_ABbEq9M</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>de Thé, Hugues</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-1113-4472</orcidid></search><sort><creationdate>20180201</creationdate><title>Differentiation therapy revisited</title><author>de Thé, Hugues</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-f944553102bb11070031f75a21ca9e559b5da84d28fdca3779d950ead910cd5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>631/136/142</topic><topic>631/67/1059</topic><topic>631/67/1990/283/1897</topic><topic>631/67/395</topic><topic>Arsenic</topic><topic>Binding sites</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cell differentiation</topic><topic>Cell self-renewal</topic><topic>Chemotherapy</topic><topic>Cytokines</topic><topic>Health aspects</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Life Sciences</topic><topic>Oncology, Experimental</topic><topic>opinion-2</topic><topic>Phenotypes</topic><topic>Proteins</topic><topic>Retinoic acid</topic><topic>Stem cells</topic><topic>Success</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Thé, Hugues</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Nature Reviews. Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Thé, Hugues</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differentiation therapy revisited</atitle><jtitle>Nature Reviews. Cancer</jtitle><stitle>Nat Rev Cancer</stitle><addtitle>Nat Rev Cancer</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>18</volume><issue>2</issue><spage>117</spage><epage>127</epage><pages>117-127</pages><issn>1474-175X</issn><eissn>1474-1768</eissn><abstract>Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
The concept of differentiation therapy emerged from the fact that hormones or cytokines may promote differentiation
ex vivo
, thereby irreversibly changing the phenotype of cancer cells. Its hallmark success has been the treatment of acute promyelocytic leukaemia (APL), a condition that is now highly curable by the combination of retinoic acid (RA) and arsenic. Recently, drugs that trigger differentiation in a variety of primary tumour cells have been identified, suggesting that they are clinically useful. This Opinion article analyses the basis for the clinical successes of RA or arsenic in APL by assessing the respective roles of terminal maturation and loss of self-renewal. By reviewing other successful examples of drug-induced tumour cell differentiation, novel approaches to transform differentiating drugs into more efficient therapies are proposed.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29192213</pmid><doi>10.1038/nrc.2017.103</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1113-4472</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1474-175X |
ispartof | Nature Reviews. Cancer, 2018-02, Vol.18 (2), p.117-127 |
issn | 1474-175X 1474-1768 |
language | eng |
recordid | cdi_proquest_miscellaneous_1971658418 |
source | Nature; Alma/SFX Local Collection |
subjects | 631/136/142 631/67/1059 631/67/1990/283/1897 631/67/395 Arsenic Binding sites Biomedicine Cancer Cancer Research Cancer therapies Cell differentiation Cell self-renewal Chemotherapy Cytokines Health aspects Kinases Leukemia Life Sciences Oncology, Experimental opinion-2 Phenotypes Proteins Retinoic acid Stem cells Success Tumors |
title | Differentiation therapy revisited |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A09%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differentiation%20therapy%20revisited&rft.jtitle=Nature%20Reviews.%20Cancer&rft.au=de%20Th%C3%A9,%20Hugues&rft.date=2018-02-01&rft.volume=18&rft.issue=2&rft.spage=117&rft.epage=127&rft.pages=117-127&rft.issn=1474-175X&rft.eissn=1474-1768&rft_id=info:doi/10.1038/nrc.2017.103&rft_dat=%3Cgale_hal_p%3EA524724911%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2022111147&rft_id=info:pmid/29192213&rft_galeid=A524724911&rfr_iscdi=true |